• May 1, 2013 – 14:08

    Naftopidil in the Management of BPH

    Naftopidil has affinity for both α1A- and α1D-adrenoreceptors for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS).  It was originally developed as an α-adrenoceptor antagonistic anti-hypertensive drug.  It has been evaluated in both prazosin-controlled and double-blind-controlled trials in Japan that verified dose-dependent effects, and therefore has had an indication for treatment of BPH in Japan, China, and South Korea.  Several tamsulosin-controlled trials have suggested a potentially higher efficacy for alleviating storage symptoms with naftopidil.  The optimal dose is 50-75mg per day according to characteristics including baseline IPSS.  Well-designed randomized trials are warranted to confirm long-term outcomes regarding management of men with storage symptoms including nocturia, through comparisons of quality of life measures with other α-adrenergic blockers.

    Reference: Hara N, Mizusawa T, Obara K, Takahashi K.  The role of naftopidil in the management of benign prostatic hyperplasia.  Ther Adv Urol 2013;5(2)111-119.